RGB 03 (rituximab biosimilar) / Stada, Gedeon Richter - LARVOL DELTA

[VIRTUAL] REAL WORLD CLINICAL EFFECTIVENESS AND SAFETY OF CT-P10 IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A EUROPEAN NON-INTERVENTIONAL POST AUTHORIZATION SAFETY STUDY (EHA 2021) - "Over three quarters of patients initiated on CT-P10 achieved complete or partial response by 30 months, with CT-P10 appearing to be generally well tolerated by patients. The response and survival rates and overall safety profile for CT-P10 appear consistent with those reported for reference rituximab, supporting CT-P10 use in combination with chemotherapy as a therapeutic option for DLBCL."

Clinical • Real-world evidence • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Rheumatology

Stada: Capital Markets Day 2016 (Stada) - Anticipated launch in hematological malignancies and autoimmune disorders in 2019

Anticipated biosimilar launch • Biosimilar

Stada: Annual Report 2015 (Stada) - Anticipated approval in 2018

Anticipated regulatory • Biosimilar